As global markets navigate through heightened geopolitical tensions and economic uncertainties, Sweden's stock market has shown resilience amid these challenges. With European indices experiencing a downturn due to Middle East conflicts and potential policy shifts by the European Central Bank, investors are keenly observing growth companies with high insider ownership for their potential stability and alignment of interests. In this context, identifying stocks with strong insider ownership can be beneficial as it often indicates confidence in the company's long-term prospects by those closest to its operations.
Name | Insider Ownership | Earnings Growth |
CTT Systems (OM:CTT) | 16.9% | 24.8% |
Truecaller (OM:TRUE B) | 29.6% | 21.6% |
Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
Biovica International (OM:BIOVIC B) | 18.3% | 78.5% |
BioArctic (OM:BIOA B) | 34% | 98.4% |
KebNi (OM:KEBNI B) | 36.3% | 86.1% |
Yubico (OM:YUBICO) | 37.5% | 42.3% |
InCoax Networks (OM:INCOAX) | 19.5% | 115.5% |
C-Rad (OM:CRAD B) | 16.1% | 33.9% |
OrganoClick (OM:ORGC) | 23.1% | 109.0% |
Click here to see the full list of 79 stocks from our Fast Growing Swedish Companies With High Insider Ownership screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: BioArctic AB (publ) is a Swedish company focused on developing biological drugs for central nervous system disorders, with a market cap of SEK14.15 billion.
Operations: The company's revenue is primarily derived from its biotechnology segment, amounting to SEK299.35 million.
Insider Ownership: 34%
Revenue Growth Forecast: 42.4% p.a.
BioArctic is experiencing significant growth, with revenue forecasted to increase by 42.4% annually, surpassing the Swedish market average. Despite a recent net loss, there are signs of improvement with reduced losses compared to last year. Insider activity shows more buying than selling recently, albeit not in substantial volumes. The company's strategic partnership with Eisai for Alzheimer's treatment Leqembi highlights its innovative potential and could enhance future profitability without incurring development costs for this drug.
Simply Wall St Growth Rating: ★★★★★★
Overview: CTT Systems AB (publ) designs, manufactures, and sells humidity control systems for aircraft across Sweden, Denmark, France, the United States, and internationally with a market cap of SEK3.36 billion.
Operations: The company's revenue primarily stems from its Aerospace & Defense segment, amounting to SEK317.70 million.
Insider Ownership: 16.9%
Revenue Growth Forecast: 21.9% p.a.
CTT Systems is experiencing robust growth, with revenue expected to rise by 21.9% annually, outpacing the Swedish market. Earnings are forecast to grow significantly at 24.8% per year, and the company trades below its estimated fair value. Insider activity has been positive with more buying than selling recently. Recent inclusion in the S&P Global BMI Index and stable earnings performance further bolster its growth outlook despite an unstable dividend track record.
Simply Wall St Growth Rating: ★★★★★★
Overview: Yubico AB offers authentication solutions for computers, networks, and online services, with a market cap of SEK23.51 billion.
Operations: The company generates revenue of SEK2.09 billion from its Security Software & Services segment.
Insider Ownership: 37.5%
Revenue Growth Forecast: 20.5% p.a.
Yubico is demonstrating strong growth potential, with earnings projected to increase by 42.3% annually, significantly surpassing the Swedish market average. Revenue is also expected to grow at 20.5% per year, indicating robust market demand for its security solutions like YubiKeys, recently adopted by PKO Bank Polski for enhanced e-banking security. Despite a volatile share price and lower profit margins this year, Yubico's strategic partnerships and innovative product offerings support its growth trajectory.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include OM:BIOA B OM:CTT and OM:YUBICO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。